Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ABEO

ABEO - Abeona Therapeutics Inc Stock Price, Fair Value and News

5.38USD-0.01 (-0.19%)Delayed as of 16 Jul 2024, 11:02 am ET

Market Summary

ABEO
USD5.38-0.01
Delayedas of 16 Jul 2024, 11:02 am
-0.19%

ABEO Alerts

  • 2 major insider sales recently.

ABEO Stock Price

View Fullscreen

ABEO RSI Chart

ABEO Valuation

Market Cap

222.0M

Price/Earnings (Trailing)

-2.9

Price/Sales (Trailing)

63.43

Price/Free Cashflow

-5.46

ABEO Price/Sales (Trailing)

ABEO Profitability

Return on Equity

863.18%

Return on Assets

-102.45%

Free Cashflow Yield

-18.31%

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

3.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ABEO Earnings

Earnings (TTM)

-76.7M

Earnings Growth (Yr)

-246.74%

Earnings Growth (Qtr)

-90.33%

Breaking Down ABEO Revenue

52 Week Range

2.835.52
(Low)(High)

Last 7 days

11.3%

Last 30 days

16.9%

Last 90 days

-31.2%

Trailing 12 Months

37.6%

How does ABEO drawdown profile look like?

ABEO Financial Health

Current Ratio

5.61

Debt/Equity

-2.04

Debt/Cashflow

-2.2

ABEO Investor Care

Shares Dilution (1Y)

119.33%

Diluted EPS (TTM)

-2.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20231.9M2.5M3.0M3.5M
20221.7M1.6M1.5M1.4M
20210001.8M
20200010.0M12.2M
20186.9M7.5M9.0M9.3M
20171.0M843.0K878.0K837.0K
20161.3M1.4M1.5M1.1M
2015358.9K672.8K986.6K1.3M
20141.0M806.0K853.0K45.0K
20133.8M3.6M2.9M2.0M
20123.5M4.1M3.9M4.4M
20112.0M1.9M1.9M1.8M
20100002.0M

Tracking the Latest Insider Buys and Sells of Abeona Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 08, 2024
wuchterl donald a.
acquired
-
-
23,611
-
Jul 08, 2024
amoroso michael
acquired
-
-
23,611
-
Jul 08, 2024
alland leila
acquired
-
-
23,611
-
Jul 08, 2024
silverstein christine berni
acquired
-
-
23,611
-
Jul 08, 2024
charles faith l.
acquired
-
-
23,611
-
Jul 08, 2024
o'malley brendan m.
acquired
-
-
102,689
svp, general counsel
Jul 08, 2024
seshadri vishwas
acquired
-
-
424,000
chief executive officer
Jul 08, 2024
vazzano joseph walter
acquired
-
-
155,200
chief financial officer
Jul 08, 2024
alvino mark
acquired
-
-
23,611
-
Jun 18, 2024
alvino mark
sold
-116,764
4.51
-25,890
-

1–10 of 50

Which funds bought or sold ABEO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
Rosalind Advisors, Inc.
new
-
7,420,000
7,420,000
5.71%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
new
-
7,000
7,000
-%
May 20, 2024
Highlander Capital Management, LLC
unchanged
-
2.00
7.00
-%
May 17, 2024
Ikarian Capital, LLC
added
48.1
3,436,300
6,442,300
0.71%
May 16, 2024
JANE STREET GROUP, LLC
added
57.78
262,861
467,705
-%
May 15, 2024
BARCLAYS PLC
reduced
-66.77
-441,000
409,000
-%
May 15, 2024
Point72 Asset Management, L.P.
sold off
-100
-3,811,960
-
-%
May 15, 2024
Laurion Capital Management LP
new
-
4,689,520
4,689,520
0.04%
May 15, 2024
J. Goldman & Co LP
reduced
-94.71
-1,988,440
164,938
-%
May 15, 2024
Walleye Capital LLC
added
41.54
987,367
1,929,330
-%

1–10 of 42

Are Funds Buying or Selling ABEO?

Are funds buying ABEO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABEO
No. of Funds

Unveiling Abeona Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 03, 2024
adage capital management, l.p.
9.99%
4,210,429
SC 13G/A
May 13, 2024
suvretta capital management, llc
9.3%
3,685,503
SC 13G
May 09, 2024
janus henderson group plc
6.1%
2,380,667
SC 13G
Feb 14, 2024
point72 asset management, l.p.
6.4%
1,649,740
SC 13G/A
Feb 14, 2024
armistice capital, llc
4.99%
1,301,114
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
4.2%
1,086,956
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
9.9%
2,499,781
SC 13G/A
Feb 12, 2024
flynn james e
3.39%
869,565
SC 13G/A
Jan 10, 2024
integrated core strategies (us) llc
5.5%
1,363,572
SC 13G/A
Dec 04, 2023
integrated core strategies (us) llc
5.4%
1,334,725
SC 13G

Recent SEC filings of Abeona Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
8-K
Current Report
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading
Jul 09, 2024
4
Insider Trading

Peers (Alternatives to Abeona Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.6B
6.8B
-13.25% 0.10%
-7.8
6.8
-64.45% -224.75%
32.4B
2.0B
59.65% 29.92%
-97.58
16.18
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.1B
2.5B
1.33% -1.46%
78.18
6.5
13.74% 186.89%
14.4B
3.8B
3.45% 4.03%
19.35
3.83
8.58% 129.81%
MID-CAP
5.2B
107.9M
- 52.91%
-9.53
48.09
54.84% -28.31%
4.9B
524.1M
-4.71% -52.64%
-11.63
9.26
394.93% 39.61%
3.9B
251.0M
12.43% 12.43%
-13.27
15.67
73.58% -86.73%
3.6B
240.7M
11.69% -16.59%
-7.58
12.77
-1.03% -213.92%
3.0B
813.8M
21.06% -43.91%
-1.7K
3.66
56.43% 98.83%
2.1B
996.6M
5.00% 74.19%
-5.32
2.13
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.22% 30.25%
30.38
4.81
60.38% -34.49%
632.3M
881.7K
18.10% 671.45%
-18.73
481.06
-77.61% 33.36%
286.3M
4.2M
21.56% 73.74%
-2.29
68.83
-66.30% 48.24%
19.8M
2.1M
-10.16% -79.46%
-0.86
7.61
-13.45% 69.54%

Abeona Therapeutics Inc News

Latest updates
MarketBeat14 Jul 202406:44 am
American Banking and Market News12 Jul 202412:13 pm
Seeking Alpha11 Jul 202403:05 pm

Abeona Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q42020Q32018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q4
Revenue----3,5001,78468.00-1,0003461,6733,0007,0004821,7098196,275215219217186256
Costs and Expenses-------------18,49218,62512,83311,2148,9655,5818,6575,4706,088
Operating Expenses8.5%14,33013,20911,33414,05412,03813,0049,3809,00820,93749,65217,48013,248-18,625-------
  S&GA Expenses22.2%7,1235,8304,1565,0213,9975,6823,8903,4604,2244,3757,3974,4327,6314,9704,627------
  R&D Expenses-2.3%7,2077,3797,1488,5238,0416,2725,4906,65810,54512,8129,2437,9699,47013,1507,916------
Interest Expenses773.4%95210910510310117815720020153.001,3881,3272.003.003.003.001.00----
Income Taxes-8.00---6.00----------------
Net Income-90.3%-31,578-16,591-11,836-16,654-9,107-7,121-6,434-4,097-22,044-46,683-15,828-7,237-17,479-16,419-12,243------
Net Income Margin-41.5%-21.90*-15.48*-15.01*-16.00*-13.83*-28.07*-52.84*-50.36*-54.41*-48.31*-----------
Free Cashflow-64.6%-15,263-9,272-5,818-10,332-11,918-14,017-6,793-9,013-13,790-33,505-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets16.9%75.0064.0066.0054.0053.0064.0039.0045.0055.0080.00119131141151159164175223143159166
  Current Assets19.7%67.0056.0057.0044.0043.0053.0025.0030.0039.0056.0068.0079.0089.0098.0010510911913250.0065.0072.00
    Cash Equivalents21.3%18.0014.005.006.005.0014.006.006.0020.0033.0044.0027.0014.0013.008.0015.0040.0012948.0043.0026.00
  Net PPE6.6%4.004.004.004.005.006.007.007.008.0012.0010.0010.0011.0011.0012.0013.0013.0013.0014.0014.0010.00
  Goodwill-----------32.0032.0032.0032.0032.0032.0032.0032.0032.0032.0032.00
Liabilities70.2%84.0049.0044.0044.0035.0037.0023.0025.0024.0037.0039.0047.0047.0049.0044.0043.0043.0045.0047.0052.0048.00
  Current Liabilities-11.4%12.0013.008.009.007.008.0013.0014.0012.0017.0026.0042.0041.0042.0039.0038.0037.0039.0020.0026.0021.00
  Long Term Debt-18.00--------------------
    LT Debt, Non Current-18.00--------------------
Shareholder's Equity-159.9%-8.8815.0022.009.0019.0027.0012.0014.0021.0042.0080.0084.0094.0010311512113217896.00107118
  Retained Earnings-4.2%-781-749-732-721-704-695688682-676-655-608-601-586-570-554-547-534-486-470-452-428
  Additional Paid-In Capital1.0%772764755730723722701694697697688685680672669668666664566559546
Shares Outstanding3.9%28.0027.0025.0021.0017.0018.006.006.006.006.004.004.004.00--------
Float----78.00---29.00---137---204---131-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-57.4%-14,538-9,235-5,774-10,256-11,744-13,992-6,791-9,013-13,687-30,257-10,334-11,489-13,585-1,610-10,702-9,475-13,232-14,246-18,254-15,242-15,078
  Share Based Compensation2.1%1,5461,5141,5579277708336327248622,0012,5372,4281,9503,0301611471,2562,59598.001,6782,103
Cashflow From Investing-167.8%-7,81711,529-18,7435,2112,211-25,2901,649-1,3981,0757,99926,76321,9249,3765,7824,584-18,209-75,871-94619,22818,92022,774
Cashflow From Financing240.7%25,4407,46722,9766,618-4.0042,7664,189--16,3311732,4795,8783.00---96,5274,34013,00728.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABEO Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
License and other revenues
Expenses:  
Research and development7,2078,041
General and administrative7,1233,997
Total expenses14,33012,038
Loss from operations(14,330)(12,038)
Interest income843364
Interest expense(952)(101)
Change in fair value of warrant and derivative liabilities(17,301)2,265
Other income162403
Net loss$ (31,578)$ (9,107)
Loss per common share - basic$ (1.16)$ (0.54)
Loss per common share - diluted$ (1.16)$ (0.54)
Weighted average number of common shares outstanding - basic27,315,53716,904,024
Weighted average number of common shares outstanding - diluted27,315,53716,904,024
Other comprehensive income (loss):  
Change in unrealized (losses) gains related to available-for-sale debt securities$ (118)$ 64
Comprehensive loss$ (31,696)$ (9,043)

ABEO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 17,558$ 14,473
Short-term investments44,78637,753
Restricted cash338338
Other receivables2,2322,444
Prepaid expenses and other current assets1,811729
Total current assets66,72555,737
Property and equipment, net3,7673,533
Operating lease right-of-use assets4,2224,455
Other assets114277
Total assets74,82864,002
Current liabilities:  
Accounts payable3,3621,858
Accrued expenses2,7915,985
Current portion of operating lease liability1,044998
Current portion of payable to licensor4,6914,580
Other current liabilities11
Total current liabilities11,88913,422
Long-term operating lease liabilities4,0464,402
Long-term debt18,079
Derivative liabilities1,005
Warrant liabilities48,69031,352
Total liabilities83,70949,176
Commitments and contingencies
Stockholders’ (deficit) equity:  
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Common stock - $0.01 par value; authorized 200,000,000 shares; 27,550,593 and 26,523,878 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively276265
Additional paid-in capital772,129764,151
Accumulated deficit(781,102)(749,524)
Accumulated other comprehensive loss(184)(66)
Total stockholders’ (deficit) equity(8,881)14,826
Total liabilities and stockholders’ equity$ 74,828$ 64,002
ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
 CEO
 WEBSITEabeonatherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES57

Abeona Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Abeona Therapeutics Inc? What does ABEO stand for in stocks?

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abeona Therapeutics Inc (ABEO)?

As of Mon Jul 15 2024, market cap of Abeona Therapeutics Inc is 221.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers. The fair value of Abeona Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abeona Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abeona Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

What is Abeona Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jul 15 2024, ABEO's PE ratio (Price to Earnings) is -2.9 and Price to Sales (PS) ratio is 63.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abeona Therapeutics Inc's stock?

In the past 10 years, Abeona Therapeutics Inc has provided -0.074 (multiply by 100 for percentage) rate of return.